4 July 2023: Reference is made to the stock exchange release of Vistin Pharma ASA (“Vistin” or the “Company”) dated 30 June 2023 at 07:30 hours CEST concerning an offer to buy back shares (the “Offer”) in connection with its Long Term Incentive Plan (LTIP) for the executive management. The Offer expired Monday 3 July 2023 at 16:00 hours CEST.
The Company has resolved to buy back 220 000 shares at a price of NOK 23,00 per share (the “Purchase Price”). The Purchase Price was determined through a reverse book-building process conducted by SpareBank 1 Markets AS.
As a result of the buy back, the Company owns 220 000 own shares, corresponding to 0,50% of the share capital and voting rights in the Company.
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…
Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…
LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…
Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…
A Revolutionary ATCA/VME/VXI 3D-Flow Board: 512 Channels, >2,800 Programmable Operations—Scalable to >50,000 Operations on Each…
After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…